RecallRadar
ModerateReported October 21, 2026 (6 days ago)

Tirzepatide/Niacinamide 2mL vial (40 MG per Vial) Inj 20mg/2mg/mL

Recalled by Houston Rx LLC

Drug recall

Houston Rx LLC

Class II — moderate

Using this product might cause a temporary or medically reversible health problem. The chance of serious harm is low.

Houston Rx LLC has recalled Tirzepatide/Niacinamide 2mL vial (40 MG per Vial) Inj 20mg/2mg/mL, according to data published by the U.S. Food and Drug Administration (FDA). The recall was reported on October 21, 2026 and was initiated on September 25, 2026. It is classified as a Class II recall, which means using this product might cause a temporary or medically reversible health problem. The chance of serious harm is low.

Below is a plain-English summary of what was recalled, why it was recalled, how to tell whether you have the affected product, and what steps you can take. For the complete and most current details, you can view the FDA record linked further down this page.

What was recalled?

This recall covers Tirzepatide/Niacinamide 2mL vial (40 MG per Vial) Inj 20mg/2mg/mL, with approximately 64 vials affected. The company behind the recall is Houston Rx LLC, based in Houston, TX. The FDA describes the product as: “Tirzepatide/Niacinamide 2mL vial (40 MG per Vial) Inj 20mg/2mg/mL, RX Only, Houston RX LLC, 15430 Vantage Parkway E STE 220, Houston, TX 77032.”

Why was Tirzepatide/Niacinamide 2mL vial (40 MG per Vial) Inj 20mg/2mg/mL recalled?

According to the FDA, the stated reason for the recall is: “Lack of assurance of sterility.” In plain terms, this recall relates to a sterility or contamination concern.

Sterile medicines, such as injectables and eye drops, must be completely free of microorganisms and stray particles. This recall means that sterility could not be assured or that contamination was found or suspected. Using a non-sterile product of this kind can cause infections, which is why these recalls are treated seriously.

What should you do?

If you think you may have bought Tirzepatide/Niacinamide 2mL vial (40 MG per Vial) Inj 20mg/2mg/mL, compare it against the product description and identifying codes (Lot# TZN-080326-20/2-2, Beyond Use Date: 12/01/2026.) before using it. This recall is currently listed as ongoing.

The general guidance for a matching product is to stop using it and follow the instructions in the official FDA recall notice, which may include a repair, replacement, refund, or safe disposal. When in doubt, contact Houston Rx LLC or your local health authority.

About this recall

This recall was distributed in TX. RecallRadar summarizes recall information from public FDA data to make it easier to understand. We are an independent service and are not affiliated with the FDA or any government agency, so please always refer to the official source for the authoritative record — and note the “last synced” date shown on this page, since recall details can change over time.

Who this recall affects

This recall matters to anyone who bought Tirzepatide/Niacinamide 2mL vial (40 MG per Vial) Inj 20mg/2mg/mL. Even if you feel fine, it's worth checking what you have on hand rather than assuming you were missed.

Distribution listed in the notice: Nationwide in the USA..

What sterility or contamination concern actually means

Sterile medicines, such as injectables and eye drops, must be completely free of microorganisms and stray particles. This recall means that sterility could not be assured or that contamination was found or suspected. Using a non-sterile product of this kind can cause infections, which is why these recalls are treated seriously.

In this case, the concern applies specifically to Tirzepatide/Niacinamide 2mL vial (40 MG per Vial) Inj 20mg/2mg/mL from Houston Rx LLC — not to the wider category of products. Similar items from other brands aren't part of this recall.

How to check whether you have it

On medicine bottles, the lot number and expiration date are printed on the pharmacy label or stamped directly on the manufacturer's bottle — often near the bottom edge or on the back. If a pharmacy label covers it, your pharmacist can look up the lot they dispensed.

Compare what you find against the identifying details in this recall: Lot# TZN-080326-20/2-2, Beyond Use Date: 12/01/2026.

What to do if you already bought it

Do not stop taking a prescribed medicine on your own because of a recall — for many conditions, an interrupted dose carries its own risk.

Instead, check the lot number against the details above and contact your pharmacist, who can confirm what they dispensed and arrange a replacement.

If you've had an unexpected reaction, contact your healthcare provider. Problems can also be reported to the FDA's MedWatch program.

Full recall details

Status
Ongoing
Date reported
October 21, 2026
Recall started
September 25, 2026
Distributed in
TX
What was recalled
Tirzepatide/Niacinamide 2mL vial (40 MG per Vial) Inj 20mg/2mg/mL, RX Only, Houston RX LLC, 15430 Vantage Parkway E STE 220, Houston, TX 77032.
Why it was recalled (as stated by the FDA)
Lack of assurance of sterility.
How to identify the affected product
Lot# TZN-080326-20/2-2, Beyond Use Date: 12/01/2026.
Amount recalled
64 vials

What you can do

Check whether any product you have matches the description and codes above. If it does, stop using it and follow the instructions in the official recall notice. When in doubt, contact the company or your local health authority.

Quick answers

Why was Tirzepatide/Niacinamide 2mL vial (40 MG per Vial) Inj 20mg/2mg/mL recalled?+

According to the FDA: Lack of assurance of sterility.

How serious is this recall?+

Class II — moderate. Using this product might cause a temporary or medically reversible health problem. The chance of serious harm is low.

What should I do if I have Tirzepatide/Niacinamide 2mL vial (40 MG per Vial) Inj 20mg/2mg/mL?+

Compare your product against the description and identifying codes on this page. If it matches, stop using it and follow the instructions in the official recall notice — this usually means returning it for a refund or discarding it. When in doubt, contact the company or your local health authority.

Share this recall:PostShareEmail
View the official FDA record →

Opens the U.S. Food and Drug Administration (FDA) data for this recall.

Recall number: D-0040-2027. Information last synced from the FDA on October 27, 2026.

Related recalls